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rise to confusion about drug safety. Risk perception among health 
care professionals and the public differ in many aspects, and so does 
need and quality of drug information. In this presentation, experi-
ence from regional medicines information and pharmacovigilance 
centers in Norway (RELIS) serving health care professionals are 
described. In particular, through a public service started in 2011, 
“SafeMommyMedicine,” RELIS inform pregnant and breastfeeding 
women about risk associated with use of medicines. In parallel with 
this, we focus on research projects in which our service toward both 
target groups is evaluated.
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Summary: By 2014 in the United Kingdom, a system of “value-
based pricing” (VBP) will replace the current Pharmaceutical Price 
Regulation Scheme (PPRS), which is a voluntary agreement between 
the UK Department of Health (DH) and the pharmaceutical indus-
try whereby companies negotiate profit rates from drug sales to the 
National Health Service (NHS) every 5 years. The concept of VBP is 
that prices of individual pharmaceutical products should reflect their 
“clinical and therapeutic value to patients and the broader NHS.” 
This talk describes a potential framework for VBP in the type of 
devolved NHS envisioned in recent UK government reforms. It also 
considers some of the critical features of VBP arrangements that 
need to be appropriately specified if the potential benefits are to be 
realized. The introduction of VBP provides an opportunity to found 
pharmaceutical pricing and access to new health technologies on 
sound principles, reflective of social values and the reality of a budget-
constrained NHS. This requires clarity on key issues of principle and 
social value, as well as critical details of how it will be implemented 
and operate. Any assessment of value must be founded on the type 
of transparent scientific assessment of the costs and benefits offered 
by a technology that is already embodied in the National Institute 
for Health and Care Excellence (NICE) appraisal process. It is also 
important that the assessment of the health expected to be forgone 
elsewhere in the NHS due to additional costs displacing other NHS 
activities (ie, the cost-effectiveness threshold) is evidence based. In 
addition, transparent rules of how prices might be negotiated based 
on such assessments are required.
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Summary: Sjölin-Forsberg, G. and Fluss, S.S.
The Council for International Organizations of Medical Sciences 
(CIOMS) was established by WHO and UNESCO in 1949. One of its 
major objectives has been to contribute to harmonized approaches to 
international systems and terminology used for the safety surveillance 
of medicinal products and vaccines by the publication of consensus 
reports that discuss and recommend general principles. It has hence 
proved crucial to involve experts from drug regulatory authorities, 
research-based biopharmaceutical companies, WHO, academia, and 
public health bodies.
Covered areas of the life cycle of medicinal products have been 
international reporting of adverse drug reactions (the CIOMS I 
reporting form), Adverse Drug Reaction terminology, Standardized 
MedDRA (R) Queries (SMQs), management of safety data from clini-
cal trials, periodic drug safety updates in the pre- and postapproval 
phases, core clinical safety information on drugs under development, 
proposals for harmonized safety information in data sheets or pack-
age inserts, approaches for assessing benefit/risk, pharmacogenetics, 
and pharmacovigilance in resource-limited countries. The 2 most 
recent CIOMS publications cover safety signal detection and man-
agement1 and definition and application of terms for vaccine phar-
macovigilance.2
The ongoing CIOMS Working Group on Practical Considerations 
for Development and Application of a Toolkit for Medicinal Product 
Risk Management has undertaken the challenging task of defining 
fundamental principles that should underlie efforts to minimize or 
mitigate the risks associated with medicines. Risk management also 
involves interaction with health care systems and to increase the 
likelihood of relevance, acceptability, and feasibility of the risk mini-
mization strategy a stakeholder subgroup within Working Group IX 
considered the input from patients, physicians, other HCPs, health 
insurance carriers, and reimbursement bodies.
Meta-analyses and systematic reviews have been increasingly 
used in the scientific evaluation of efficacy and safety for benefit/risk 
assessments, as well as the pricing and reimbursement of biopharma-
ceutical products in clinical practice. CIOMS currently has an ongo-
ing Working Group aimed at developing a consensus on scientific and 
methodological criteria that represent good practices when applied to 
meta-analyses of clinical data within the regulatory process.
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Summary: Lipid-lowering therapy with statins has become the 
cornerstone in the prevention of (recurrent) cardiovascular disease 
(CVD). Statins reduce low-density lipoprotein (LDL)-cholesterol by 
30% to 60% and CVD risk by 25% to 30%. Recent European guide-
lines recommend a LDL-cholesterol goal of < 2.5 mmol/L in patients 
with high CVD risk and even lower in patients with very high risk, 
< 1.8 mmol/L or ≥ 50% reduction in LDL-cholesterol. In patients 
with severe hyperlipidemia as well as in patients who are intolerant of 
statins, these goals cannot be reached. Hence, there is a need for novel 
therapeutic modalities that lower atherogenic lipoproteins in addition 
to statins or alternatively increase protective lipoproteins (HDL).
Several promising new therapeutic approaches have been devel-
oped recently. First, antisense oligonucleotides (ASOs) have been 
proven to be effective in lowering apolipoproteins. ASOs are short 
single strands of DNA that are complimentary in sequence to a seg-
ment of mRNA of specific proteins; after binding to mRNA, trans-
lation and the production of the protein are prevented. The first 
antisense inhibitor of apoB, the structural protein of the atherogenic 
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lipoproteins, lowers LDL-cholesterol on average by 28%. This com-
pound, mipomersen, is injected weekly subcutaneously.
A second agent that inhibits the formation of apoB-containing 
lipoproteins in liver and gut is an inhibitor of microsomal triglyceride 
transfer protein (MTP). This compound lowered LDL-cholesterol by 
50% in patients with homozygous familial hypercholesterolemia. 
A side effect of both classes of drugs is the accumulation of fat in 
the liver.
Proprotein convertase subtilisin/kexin type 9 serine protease 
(PCSK9) is a protease that induces degradation of LDL-receptors. 
Statins increase the concentration of PCSK9, thereby attenuating 
their LDL-cholesterol–lowering effect. Combining statins with inhibi-
tors of PCSK9 has proven to be very effective in LDL-cholesterol 
lowering: injection of monoclonal antibodies to PCSK9 biweekly 
on top of maximal statin therapy lowered LDL-cholesterol by an 
extra 60%. If long-term treatment with these antibodies proves to 
be safe, this will change the treatment of patients with severe familial 
hypercholesterolemia. The near future years will also provide the 
final verdict whether raising HDL-cholesterol by means of inhibition 
of cholesteryl ester transfer protein (CETP) will be of any benefit.
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Summary: Tumor necrosis factor-alpha (TNF-alpha) plays a role in 
the process of intraocular inflammation that is the cause that the use 
of TNF-alpha inhibitor agents is worldwide spread to treat differ-
ent form of intraocular inflammations. In ophthalmology, anti-TNFs 
are applied in the treatment of uveitis and immune-vasculitis. The 
number of TNF-alpha inhibitors is increasing despite the fact that 
such kind of medication can be used “off-label” in the treatment 
of inflammations. TNF-alpha inhibitors are effective at first in that 
form of uveitis that is connected with systemic immunologic diseases: 
Mo. Behcet, rheumatoid arthritis (especially with juvenile idiopathic 
arthritis), Mo. Chrohn, Wegener granulomatosis, autoimmune dis-
eases (lupus-like syndrome [LLS]). In cases of vasculitis, it can be 
used in giant cell arthritis, Takayasu arthritis, primary angiitis of the 
central nervous system, and Cogan syndrome. Anti–TNF-alpha also 
are effective in cases of autoimmune, noninfectious diseases of the 
eye: Mo. Harada, sympathetic ophthalmia. The most frequent anti–
TNF-alpha that are used are etanercept, adalimumab, and infliximab. 
There are 3 other TNF-alpha inhibitors that are less widespread yet: 
golimumab, certolizumab, and tocilizumab. The advantage of the 
TNF-alpha inhibitors are that they have fewer side effects as corti-
costeroids and immunsuppressives but are more effective. Their only 
disadvantage: they are very expensive.
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Summary: With the increasing needs for better outcome, func-
tion, and quality of life in arthritides and autoimmune diseases, we 
have increasing amounts of information on the major pathogenetic 
pathways underlying rheumatoid arthritis (RA), spondyloarthriti-
des (SpA), lupus, scleroderma, and other rheumatic diseases. After 
decades of reliance on largely empiric approaches in the therapy 
of most of these diseases, the introduction of TNF-alpha–blocking 
agents in the late 1990s revolutionized the therapy of rheumatoid 
arthritis (RA), other arthritides, and connective tissue diseases. 
Numerous pathways have been targeted and almost 10 biologics 
have been registered to treat RA, SpA, and lupus. In addition to 
anti-TNF biologics, further therapies such as anti–IL-6R, CTLA4-
inhibitor, or anti-CD20 agents along with several new experimental 
approaches have since emerged out of improved understanding of 
the immunopathogenesis. In addition to biologics, the first small 
molecular targeted therapies, mostly tyrosine kinase inhibitors, have 
been developed. Most therapies primarily intended for RA, however, 
have failed to show or have shown only marginal benefit in other 
autoimmune rheumatic diseases such as lupus, scleroderma, poly-
myositis, or vasculitides, all of which continue to have a high unmet 
medical need. Challenges to identify novel drug candidates and to 
conduct successful clinical studies for such diseases include the dif-
ferent and highly complex immunopathology as well as clinical 
trial–related issues (eg, the lack of validated, sensitive, and reliable 
end points). Recently, promising new therapeutic approaches have 
emerged. This presentation highlights these advances in autoimmune 
rheumatic diseases.
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Summary: In the last decades, both regulators and manufactur-
ers have used computerized data-mining techniques on reports 
of adverse drug reactions from both health care practitioners and 
consumers to detect drug safety signals, that is, unknown or incom-
pletely documented drug-event associations. The signal detection 
using data from spontaneous reporting system (SRS) databases is 
negatively influenced however by under- and selective reporting as 
well as missing denominators. To overcome some of these shortcom-
ings, in the last 5 years, a number of ongoing international initia-
tives (Sentinel, Protect, OMOP, EU-ADR) has started to explore 
longitudinal observational health care data, including electronic 
health records (EHRs), as an additional source for signal detec-
tion. The ultimate goal of the EU-ADR project was to develop an 
innovative, computerized system for the automatic detection of drug 
safety signals. Using a database network of 7 databases from 3 coun-
tries covering ~30 million European patients, EU-ADR developed 
new methodologies for signal detection and compared the perfor-
mance (both in terms of precision and timing) of signal detection 
using either EHRs or SRS through validation sets. Main findings 
of the project are that EU-ADR is not powered enough to monitor 
infrequently used/captured drugs and associations regarding very 
rare events, while SRS may be more efficient. On the other hand, 
EU-ADR has the most power for signal detection concerning events 
with higher incidences rate and not commonly reported to SRS. In 
this presentation, the overview of methodology and results from 
EU-ADR will be presented and the potentially additional value of 
exploring EHRs in the context of pharmacovigilance will be dis-
cussed.
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